The ability of GLP-1 RAs to penetrate the blood–brain barrier and mediate central effects (e.g., appetite suppression) can differ based on the molecular structure of the agonist and individual patient characteristics such as blood–brain barrier permeability, obesity, and metabolic health. Here, GLP1R is linked to obesity disorder.